Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Long-term clinical and magnetic resonance imaging outcomes from patients treated with teriflunomide: Results from a phase 2 extension study.
Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases.
Changes in phospholipid composition of the spinal cord in rabbits with allergic encephalomyelitis as an experimental model of multiple sclerosis.
Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine.
A phase II study of laquinimod in Crohn's disease.
Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system.
Opposite Roles of NMDA Receptors in Relapsing and Primary Progressive Multiple Sclerosis.
Multiple sclerosis susceptibility genes: associations with relapse severity and recovery.
The American Academy of Neurology's Top Five Choosing Wisely recommendations.
Rehabilitation interventions in multiple sclerosis: an overview.
UW-SES: A new self-efficacy scale for people with disabilities.
Visual Functional and Histopathological Correlation in Experimental Autoimmune Optic Neuritis.
Helminth therapy and multiple sclerosis.
Progressive Multifocal Leukoencephalopathy
Multiple sclerosis and breast cancer.
A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - A twelve month follow-up.
Pharmaceutical approval update.
Epstein-Barr virus: an important vaccine target for cancer prevention.
ISMRM Workshop on Multiple Sclerosis as a Whole-Brain Disease
Time limited immunomodulatory functions of transplanted neural precursor cells.
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
First use of alemtuzumab in Balo's concentric sclerosis: a case report.
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
Apitope Announces Completion of Enrolment in Phase IIA Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.

Pages